Know Cancer

forgot password

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy

18 Years
Open (Enrolling)
Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer

Thank you

Trial Information

A Pilot Study of Vorinostat to Restore Sensitivity to Aromatase Inhibitor Therapy


I. Determine the rate of clinical benefit (objective response plus stable disease) for
patients treated with cycles consisting of 2 weeks of vorinostat followed by 6 weeks of AI


I. Assess the safety and tolerability of vorinostat in patients with metastatic breast

II. Assess the change in estrogen receptor (ER) expression, measured as the change in
fluoroestradiol standard uptake value (FES SUV) using fluoroestradiol-positron emission
tomography (FES-PET) completed per protocol 7184 after two weeks of vorinostat therapy and
after 8 weeks of therapy.

III. Assess tumor metabolic response, measured as the change in fluorodeoxyglucose (FDG) SUV
using FDG PET completed per protocol 7184 after two weeks of vorinostat therapy and after 8
weeks of therapy.

IV. Assess the change in hormone levels (estradiol, estrone, follicle-stimulating hormone
[FSH], sex binding globulin, testosterone, and free testosterone) after 8 weeks of therapy.

V. Assess the change in ER, progesterone receptor (PR), human epidermal growth factor
receptor 2 (HER2), androgen receptor (AR), epithelial growth factor receptor (EGFR),
vascular endothelial growth factor (VEGF) tumor expression after two weeks of vorinostat
therapy in patients that consent to optional tissue biopsy procedure.

VI. Assess the time to progression and the overall survival of patients treated with cycles
of 2 weeks of vorinostat followed by 6 weeks of AI.


Patients receive vorinostat orally (PO) once daily (QD) for 2 weeks followed by AI therapy
comprising anastrozole PO QD, letrozole PO QD, OR exemestane PO QD for 6 weeks. Courses
repeat every 8 weeks in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years,
every 6 months until disease progression, and then annually thereafter.

Inclusion Criteria:

- Histologically or cytologically proven diagnosis of breast cancer

- Stage IV disease

- Patient has previously derived clinical benefit from endocrine therapy, but is no
longer deriving benefit to endocrine therapy in the opinion of the treating
investigator; patients need to stop AI for at least one week prior to starting
vorinostat treatment on this protocol

- At least one site of measurable disease, as defined by the modified Response
Evaluation Criteria in Solid Tumors (RECIST) criteria

- Eastern Cooperative Oncology Group (ECOG) performance status 0-2

- Female patient is post menopausal as defined by one of the following; free from
menses for > 2 years, surgically sterilized ,FSH and Estradiol in post-menopausal
range AND surgical absence of uterus OR chemotherapy induced amenorrhea lasting > 1
year OR currently on ovarian suppression

- Female patient of childbearing potential has a negative urine or serum (beta-human
chorionic gonadotropin [hCG]) pregnancy test within 14 days prior to receiving the
first dose of vorinostat

- Male patient agrees to use two barrier methods of contraception or abstain from
intercourse for the duration of the study

- Absolute neutrophil count (ANC) >= 1,500/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 9 g/dL

- Prothrombin Time or international normalized ratio (INR) =< 1.5 x upper limit of
normal (ULN) unless receiving therapeutic anticoagulation

- Partial thromboplastin time (PTT) =< 1.2 times the ULN unless the patient is
receiving therapeutic anticoagulation

- Potassium and magnesium levels within normal limits

- Calculated creatinine clearance >= 30 mL/min

- Serum total bilirubin =< 1.5 X ULN

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2.5 X

- Alkaline Phosphatase =< 2.5 X ULN

- Patient, or the patient's legal representative, has voluntarily agreed to participate
by giving written informed consent

- Patient has a life expectancy of at least 12 weeks in the opinion of the treating

- Patient is willing to continue on same AI therapy

- Patient agrees to participate in imaging Protocol 7184 and is separately consented

Exclusion Criteria:

- Patient has not derived clinical benefit from prior endocrine therapy

- Patient is currently participating or has participated in a study with an
investigational compound or device within 30 days of initial dosing with study
drug(s) other than the imaging protocol 7184

- Patient has received an ER blocking therapy (selective estrogen receptor modulating
[SERM] or downregulating [SERD] i.e. tamoxifen or fulvestrant) within the past 6

- Patient had prior treatment with an histone deacetylase (HDAC) inhibitor (e.g.,
romidespin [Depsipeptide], NSC-630176, MS 275, LAQ-824, belinostat [PXD-101], LBH589,
MGCD0103, CRA024781, etc); patients who have received compounds with HDAC
inhibitor-like activity, such as valproic acid, as anti-tumor therapy should not
enroll in this study; patients who have received such compounds for other
indications, e.g. valproic acid for epilepsy, may enroll after a 30-day washout

- Patient is on any systemic steroids that have not been stabilized to the equivalent
of =<10 mg/day prednisone during the 30 days prior to the start of the study drugs

- Patient has known hypersensitivity to the components of study drug or its analogs

- Patients with uncontrolled brain metastases

- New York Heart Association (NYHA) Class III or IV congestive heart failure,
myocardial infarction within the previous 6 months, corrected QT interval (QTc) >
0.47 seconds, or uncontrolled arrhythmia.

- Type I Diabetes Mellitus; patients with Type II Diabetes Mellitus will be included as
long as their glucose can be controlled to under 200 mg/dL

- Patient is pregnant or breast feeding, or expecting to conceive or father children
within the projected duration of the study

- Patient with a "currently active" second malignancy, other than non-melanoma skin
cancer and carcinoma in situ of the cervix, should not be enrolled; patients are not
considered to have a "currently active" malignancy if they have completed therapy for
a prior malignancy, are disease free from prior malignancies for > 5 years or are
considered by their physician to be at less than 30% risk of relapse

- Patients with known active viral hepatitis

- Patient has a history or current evidence of any condition, therapy, or lab
abnormality that might confound the results of the study, interfere with the
patient's participation for the full duration of the study or is not in the best
interest of the patient to participate

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Rate of clinical benefit

Outcome Description:

A 95% score (Wilson) confidence interval will be computed for the response rate and the rate of clinical benefit. The radiological (by computed tomography [CT]) response rate of vorinostat will be determined by tumor measurements assessed by modified RECIST criteria.

Outcome Time Frame:

Up to approximately 5 years

Safety Issue:


Principal Investigator

Hannah Linden

Investigator Role:

Principal Investigator

Investigator Affiliation:

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium


United States: Institutional Review Board

Study ID:




Start Date:

November 2010

Completion Date:

Related Keywords:

  • Male Breast Cancer
  • Recurrent Breast Cancer
  • Stage IV Breast Cancer
  • Breast Neoplasms
  • Breast Neoplasms, Male



Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium Seattle, Washington  98109